[
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV): A Bull Case Theory",
    "summary": "We came across a bullish thesis on AbbVie Inc. (ABBV) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc. (ABBV)’s share was trading at $198.47 as of May 2nd. ABBV’s trailing and forward P/E were 84.82 and 16.34 respectively according to Yahoo Finance. AbbVie (ABBV) delivered a strong […]",
    "url": "https://finnhub.io/api/news?id=666731d85e84f77f00b616695cd4bf2130857f8b9de5b5f1b7932fc86047e543",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746644048,
      "headline": "AbbVie Inc. (ABBV): A Bull Case Theory",
      "id": 134316717,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on AbbVie Inc. (ABBV) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc. (ABBV)’s share was trading at $198.47 as of May 2nd. ABBV’s trailing and forward P/E were 84.82 and 16.34 respectively according to Yahoo Finance. AbbVie (ABBV) delivered a strong […]",
      "url": "https://finnhub.io/api/news?id=666731d85e84f77f00b616695cd4bf2130857f8b9de5b5f1b7932fc86047e543"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Johnson & Johnson and AbbVie",
    "summary": "Johnson & Johnson and AbbVie are part of the Zacks top Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=ba0ced5728642acfb936ea14cc39df5f9bbb0da54d4ada854b24eb9b07b480a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746622080,
      "headline": "The Zacks Analyst Blog Highlights Johnson & Johnson and AbbVie",
      "id": 134316707,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Johnson & Johnson and AbbVie are part of the Zacks top Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=ba0ced5728642acfb936ea14cc39df5f9bbb0da54d4ada854b24eb9b07b480a9"
    }
  },
  {
    "ts": null,
    "headline": "2024 Total Dividend Income And Portfolio Update",
    "summary": "2024 also saw some changes to some of my holdings as the author shuttled several dividend income payers for higher return crypto plays. Click to read.",
    "url": "https://finnhub.io/api/news?id=e84a491388932db92b15edae67d11240e3b812c212aa814a6209bef6a4a9af74",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746617700,
      "headline": "2024 Total Dividend Income And Portfolio Update",
      "id": 134296532,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2007398242/image_2007398242.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "2024 also saw some changes to some of my holdings as the author shuttled several dividend income payers for higher return crypto plays. Click to read.",
      "url": "https://finnhub.io/api/news?id=e84a491388932db92b15edae67d11240e3b812c212aa814a6209bef6a4a9af74"
    }
  },
  {
    "ts": null,
    "headline": "Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better.",
    "summary": "No matter how high President Trump cranks up tariffs, many industries are never coming back to the U.S. For industries that require cheap labor such as apparel and toys, bringing that production to Pennsylvania or Ohio just doesn’t make sense.  For pharma, an industry in which gross margins are among the highest in the S&P 500, labor was never really the reason for moving offshore to places like Ireland—it was always about playing the global tax game.  Tariffs are certainly getting pharma CEOs to listen, and many are already stockpiling imports while expanding production within existing U.S. sites.",
    "url": "https://finnhub.io/api/news?id=512783ad2d9aa1e7456f3a2962dbe67b29d04ccd17bd69f941e0fe954b32f962",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746610200,
      "headline": "Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better.",
      "id": 134316719,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "No matter how high President Trump cranks up tariffs, many industries are never coming back to the U.S. For industries that require cheap labor such as apparel and toys, bringing that production to Pennsylvania or Ohio just doesn’t make sense.  For pharma, an industry in which gross margins are among the highest in the S&P 500, labor was never really the reason for moving offshore to places like Ireland—it was always about playing the global tax game.  Tariffs are certainly getting pharma CEOs to listen, and many are already stockpiling imports while expanding production within existing U.S. sites.",
      "url": "https://finnhub.io/api/news?id=512783ad2d9aa1e7456f3a2962dbe67b29d04ccd17bd69f941e0fe954b32f962"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Select Health Care Portfolio Q1 2025 Commentary",
    "summary": "For Q1 2025, the Fidelity Select Health Care Portfolio returned -1.03%, underperforming the MSCI health care index. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=6de8cddaa404b5ed7aba0e6986a76a56106ac275d4255bad0da9cb9c149ff259",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746593700,
      "headline": "Fidelity Select Health Care Portfolio Q1 2025 Commentary",
      "id": 134290307,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/91598774/image_91598774.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "For Q1 2025, the Fidelity Select Health Care Portfolio returned -1.03%, underperforming the MSCI health care index. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=6de8cddaa404b5ed7aba0e6986a76a56106ac275d4255bad0da9cb9c149ff259"
    }
  },
  {
    "ts": null,
    "headline": "If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now?",
    "summary": "AbbVie Inc. (NYSE:ABBV), a biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. If You Bought AbbVie Stock 10 Years Ago The company's stock traded at ...",
    "url": "https://finnhub.io/api/news?id=6290ffcd80e5bf39e0abe165adcd6f42f5cf6c97d802ba248c131dfa97d285e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746584023,
      "headline": "If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now?",
      "id": 134290167,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV), a biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. If You Bought AbbVie Stock 10 Years Ago The company's stock traded at ...",
      "url": "https://finnhub.io/api/news?id=6290ffcd80e5bf39e0abe165adcd6f42f5cf6c97d802ba248c131dfa97d285e9"
    }
  }
]